PHARMACEUTICAL COMPOSITION FOR TREATING CANCER USING CARBONATE APATITE NANOPARTICLES

• US 20140302145A1
• Filed: 08/27/2013
• Published: 10/09/2014
• Est. Priority Date: 11/28/2012
• Status: Active Grant

• Current Assignee: Ijunkai, Masaki Mori, Toshihiro Akaike, Yuichiro Doki
• Original Assignee: Ijunkai, Xin Wu
• Inventors: YAMAMOTO, HIROFUMI, NAKANISHI, HIROYUKI, AKAIKE, TOSHIHIRO, MORI, MASAKI, DOKI, YUICHIRO, WU, XIN
• Granted Patent: US 9,295,640 B2
• Time in Patent Office: Days
• US Class Current: 424/489
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/5115 Inorganic compounds
• CPC Class Codes: C12N 15/111 General methods applicable to biologically active non-coding nucleic acids
• CPC Class Codes: C12N 2320/32 Special delivery means, e.g. tissue-specific

Abstract

A principal object of the present invention is to provide a pharmaceutical composition that can produce a high antitumor effect by efficiently delivering a drug with antitumor activity to tumor tissues with the aid of carbonate apatite nanoparticles. The present invention provides a pharmaceutical composition including carbonate apatite nanoparticles with an average particle size of at most 50 nm containing a drug with antitumor activity and a pharmacologically acceptable solvent in which the carbonate apatite nanoparticles containing the drug are dispersed.

Claims

1. A pharmaceutical composition, comprising:

carbonate apatite nanoparticles with an average particle size of at most 50 nm containing a drug with antitumor activity; and

a pharmacologically acceptable solvent in which the carbonate apatite nanoparticles containing the drug are dispersed.

2. The pharmaceutical composition according to claim 1, wherein the solvent is a saline solution.

3. The pharmaceutical composition according to claim 1, wherein the carbonate apatite nanoparticles are a product obtained by subjecting, to an ultrasonic vibration treatment, carbonate apatite particles containing the drug with antitumor activity.

4. The pharmaceutical composition according to claim 1, wherein the drug is at least one selected from the group consisting of siRNA, miRNA, and antisense RNA.

5. The pharmaceutical composition according to claim 1, further comprising albumin.

12. A method for manufacturing the pharmaceutical composition according to claim 1, comprising the steps of:

preparing a dispersion including carbonate apatite particles containing a drug with antitumor activity and a pharmacologically acceptable solvent in which the particles are dispersed; and

subjecting the dispersion to an ultrasonic vibration treatment.

6. A method of treating cancer, comprising the step of administering, to a patient with cancer, a pharmaceutical composition comprising carbonate apatite nanoparticles with an average particle size of at most 50 nm containing a drug with antitumor activity and a pharmacologically acceptable solvent in which the carbonate apatite nanoparticles containing the drug are dispersed.

7. The method according to claim 6, wherein the pharmaceutical composition is administered by intravascular administration, subcutaneous administration, or intramuscular administration.

8. The method according to claim 6, wherein the solvent is a saline solution.

9. The method according to claim 6, wherein the carbonate apatite nanoparticles are a product obtained by subjecting, to an ultrasonic vibration treatment, carbonate apatite particles containing the drug with antitumor activity.

10. The method according to claim 6, wherein the drug is at least one selected from the group consisting of siRNA, miRNA, and antisense RNA.

11. The method according to claim 6, wherein the pharmaceutical composition further comprises albumin.